Scorpion Capital · research-note
Harmony Biosciences (HRMY)
366 pages · 4 arc beats · 2 loops
Harmony Biosciences (HRMY)
Scorpion Capital · 2023-03 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
120406080100120140160180200220240260280300320340360366
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 70 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Setup & Stakes 10 slides 100% 10/10 slides 100% 10/10 slides · 50 hits — 0/10 slides
50% 5/10 slides 20% 2/10 slides 100% 10/10 slides — 0/10 slides
The Monster 20 slides 100% 20/20 slides 100% 20/20 slides · 136 hits — 0/20 slides
20% 4/20 slides 50% 10/20 slides 100% 20/20 slides 55% 11/20 slides The Struggle 20 slides 100% 20/20 slides 100% 20/20 slides · 139 hits — 0/20 slides
5% 1/20 slides 55% 11/20 slides 100% 20/20 slides 5% 1/20 slides The Victory 20 slides 100% 20/20 slides 100% 20/20 slides · 128 hits — 0/20 slides
— 0/20 slides
40% 8/20 slides 100% 20/20 slides 50% 10/20 slides Slide inventory
366 every slide · same image gating as the playbook
01
This is a short-seller research note cover page/executive summary.expose_contradiction
Open slide detailBeat · Setup & Stakes
03
The slide uses a 'villain' narrative technique by juxtaposing critical expert opinion with aggressive sales tactics and controversial industry associations.expose_contradiction
Open slide detailBeat · Setup & Stakes
04
The slide uses a direct quote to frame the company's sales practices as unethical or problematic.expose_contradiction
Open slide detailBeat · Setup & Stakes
05
The slide uses a testimonial to cast doubt on the company's reported metrics.expose_contradiction
Open slide detailBeat · Setup & Stakes
06
The slide uses highly aggressive, accusatory language to frame the report's sections.front_matter
Open slide detailBeat · Setup & Stakes
07
The slide uses a highly critical, investigative tone, framing the company as fraudulent and the drug as dangerous.summarize
Open slide detailBeat · Setup & Stakes
08
The slide uses a narrative structure to frame the drug's history as a series of red flags and industry failures.summarize
Open slide detailBeat · Setup & Stakes
09
The slide uses a list-based structure to present evidence of drug toxicity, citing specific page ranges from a larger document.summarize
Open slide detailBeat · Setup & Stakes
10
The slide uses a structured list format to present three distinct areas of clinical concern, each with corresponding reference numbers.summarize
Open slide detailBeat · Setup & Stakes
11
The slide uses a narrative-based evidence approach to build a case against the drug's safety profile.summarize
Open slide detailBeat · The Monster
12
The slide uses a highly critical, investigative tone, framing the subject as a 'scam' and a 'failed launch'.summarize
Open slide detailBeat · The Monster
13
The slide uses a 'villain critique' style to undermine the company's marketing claims.summarize
Open slide detailBeat · The Monster
14
The slide uses strong, accusatory language ('disaster', 'fraud', 'kickback scheme', 'whales') to frame the company's business model as unsustainable and illegalsummarize
Open slide detailBeat · The Monster
15
The slide uses a narrative structure to present evidence of corporate misconduct and operational failure.summarize
Open slide detailBeat · The Monster
16
Uses historical precedent (Enron/Skilling and Insys) to frame current events at Harmony (HRMY) as a potential fraud or legal violation.name_villain
Open slide detailBeat · The Monster
17
The slide uses a narrative of 'fraud' to frame the company's management and reporting practices.expose_contradiction
Open slide detailBeat · The Monster
18
The slide uses a narrative of past professional failure and alleged fraud to undermine the credibility of the current CFO.name_villain
Open slide detailBeat · The Monster
19
The slide uses a narrative structure to expose potential accounting opacity and price-driven revenue growth.expose_contradiction
Open slide detailBeat · The Monster
20
The slide uses a direct quote from an earnings call to highlight a lack of transparency and potential business risk.expose_contradiction
21
The slide uses EMA data to contradict the limited disclosure in the primary trial paper.expose_contradiction
22
The slide uses highlighted quotes to emphasize the lack of data transparency and the high patient drop-off rates.expose_contradiction
23
The slide uses direct quotes from an expert consultation to build a case for potential fraud or misrepresentation.expose_contradiction
24
The slide uses a Q&A format to present qualitative evidence of corporate malfeasance or short-termism.expose_contradiction
25
The slide uses highly critical, adversarial language ('toxic drug', 'face-planted', 'questionable French lab') to frame the company negatively.name_villain
26
The slide uses a combination of narrative argument and a supporting table of pharmacologic approaches to justify the 'difficult' commercial landscape.diagnose_problem
27
The slide uses a comparative analysis of pricing and regulatory status to undermine the competitor's market position.name_villain
28
The slide uses direct quotes from medical professionals to undermine the competitive advantage of the subject drug (Wakix).expose_contradiction
29
The slide uses a scientific diagram to explain the mechanism while simultaneously casting doubt on the underlying theory.name_villain
30
The slide uses a 'villain' narrative style to attack the legitimacy of Harmony Biosciences' IP.expose_contradiction
31
The slide argues that the patent claims are spurious because the inventors are the same as those who published the molecule in 2002, and PubChem shows prior artexpose_contradiction
Open slide detailBeat · The Struggle
32
The slide uses a narrative of past professional failure to cast doubt on current leadership.name_villain
Open slide detailBeat · The Struggle
33
The slide uses a 'before-after' style comparison of a website vs. an empty search result to discredit the subject.expose_contradiction
Open slide detailBeat · The Struggle
34
The slide uses a WSJ article as a source to expose the CEO's attempt to distance himself from a controversial business practice.expose_contradiction
Open slide detailBeat · The Struggle
35
The slide uses a narrative of past misconduct to establish a pattern of behavior for the subject.name_villain
Open slide detailBeat · The Struggle
36
The slide uses visual evidence (empty chair, press conference) to frame the subject as a villain in a political/regulatory context.name_villain
Open slide detailBeat · The Struggle
37
The slide uses a narrative structure to link a specific company's strategy to a broader pattern of behavior.expose_contradiction
Open slide detailBeat · The Struggle
38
The slide uses a combination of summary text and a direct testimonial quote to establish a pattern of behavior.expose_contradiction
Open slide detailBeat · The Struggle
39
The slide uses a 'short' thesis argument to frame scientific data as fraudulent.expose_contradiction
Open slide detailBeat · The Struggle
40
The slide uses a testimonial quote to support a narrative of corporate malfeasance and trial data manipulation.expose_contradiction
Open slide detailBeat · The Struggle
41
The slide uses a Q&A format to highlight potential corporate malfeasance regarding clinical trial adverse events.expose_contradiction
Open slide detailBeat · The Struggle
42
The slide uses highlighted text to emphasize key admissions regarding management's role in stopping the study.expose_contradiction
Open slide detailBeat · The Struggle
43
The slide uses a Q&A format to present qualitative evidence of internal doubt regarding clinical trial integrity.expose_contradiction
Open slide detailBeat · The Struggle
44
The slide uses direct quotes from a neurologist to cast doubt on Bioprojet's professionalism and data management.expose_contradiction
Open slide detailBeat · The Struggle
45
The slide uses a bar chart to visualize payment data from CMS OpenPayments to support a narrative of questionable marketing practices.expose_contradiction
Open slide detailBeat · The Struggle
46
The slide uses legal filings and OIG reports to establish a pattern of billing abuse in the sleep sector.expose_contradiction
Open slide detailBeat · The Struggle
47
The slide uses direct quotes from two different medical professionals to highlight a pattern of disregard for safety protocols.expose_contradiction
Open slide detailBeat · The Struggle
49
Includes a process diagram showing the progression from hERG block to Torsades de Pointes.diagnose_problem
Open slide detailBeat · The Struggle
50
The slide uses red underlining to emphasize key risk statements, likely to draw attention to the severity of the condition in the context of a drug evaluation.diagnose_problem
51
The slide uses a quote from a 2004 NEJM paper to establish a precedent of drug withdrawal, then links the molecular structure (piperidine ring) and receptor actname_villain
52
The slide uses historical news headlines to illustrate the regulatory and safety failure of the drug Seldane.cite_precedent
53
The slide uses a historical precedent (Seldane/terfenadine recall) to frame the severity of a current drug's (pitolisant) safety profile, highlighting specific cite_precedent
54
The slide uses a bar chart to compare reporting rates per million daily doses, with specific focus on drugs withdrawn from the market due to cardiac safety conccompare_peers
55
The slide uses a calculation of daily doses sold based on revenue and price to derive a rate, then compares this against historical data from a Lancet study.expose_gap
56
The slide uses a direct quote from scientific literature to establish a causal link between the drug's mechanism and its side effects.preempt_rebuttal
57
The slide uses a specific research paper abstract to validate the claim of inherent cardiotoxicity.expose_contradiction
58
Includes a visual comparison of pharmacophore models and a specific reference to ABT-239.diagnose_problem
59
The slide highlights a fundamental design constraint in medicinal chemistry.diagnose_problem
60
The slide uses visual evidence to link a specific chemical moiety (piperidine) to a known safety liability (hERG blockade).diagnose_problem
61
The slide uses a combination of narrative text and a supporting data table to argue that certain structural features are predictive of drug safety risks.preempt_rebuttal
Open slide detailBeat · The Victory
62
The slide highlights the specific chemical challenge of nitrogen basicity in piperidine rings and the potential for fluorine to modulate pKa for improved safetycite_precedent
Open slide detailBeat · The Victory
63
The slide uses a screenshot of a blog post with red underlines to emphasize key quotes about hERG activity and piperidine.cite_precedent
Open slide detailBeat · The Victory
65
The slide uses a 'before-after' or 'evidence-based' contradiction structure to undermine the value of the licensed asset.expose_contradiction
Open slide detailBeat · The Victory
66
The slide uses a 'quote-and-commentary' structure to expose potential corporate malfeasance or negligence.expose_contradiction
Open slide detailBeat · The Victory
67
The slide uses historical publication data to cast doubt on the quality of the drug pitolisant by highlighting that the inventor prioritized other compounds.expose_contradiction
Open slide detailBeat · The Victory
68
The slide uses a 'fraud-exposure' narrative, highlighting a specific omission in a scientific paper to imply corporate malfeasance.expose_contradiction
Open slide detailBeat · The Victory
69
The slide uses a question as a hook to frame the subsequent investigation.frame_problem
Open slide detailBeat · The Victory
70
The slide uses a 'villain' framing by highlighting the industry-wide failure of a specific drug class.diagnose_problem
Open slide detailBeat · The Victory
71
The slide uses a combination of chemical structure diagrams, a tabular summary of clinical trial failures, and a pie chart showing the distribution of indicatiodiagnose_problem
72
The slide highlights BF2.649 (pitolisant) with a red box to emphasize its drug-likeness profile compared to other failed candidates.cite_precedent
73
The slide uses a 'preempt_rebuttal' strategy by highlighting that even industry giants failed where the current subject company is operating.preempt_rebuttal
74
The slide uses a combination of narrative summary and a direct excerpt from a scientific review paper to validate the difficulty of the target.diagnose_problem
75
The slide uses a 'before-after' narrative structure to show that shifting chemical scaffolds did not solve the underlying safety issues in H3 receptor drug devepreempt_rebuttal
76
The slide uses excerpts from scientific literature to frame the technical hurdles in CNS drug development.diagnose_problem
77
The slide uses a 'villain critique' approach by leveraging a peer's own research to undermine the target's (Bioprojet/pitolisant) technology.expose_contradiction
78
The slide is currently empty of content other than the title, suggesting it is a placeholder or a transition slide for a section on competitor failures.name_villain
79
The slide uses a forensic literature review approach to highlight historical concerns about the drug's safety profile (cardiotoxicity, bioavailability, etc.) thexpose_contradiction
80
The slide uses a primary text block to summarize the contradiction, followed by a direct excerpt from a 2008 paper as evidence.expose_contradiction
81
The slide uses a direct quote from a scientific paper to undermine the viability of the drug candidate mentioned in the lower text block.expose_contradiction
82
The slide uses a 'villain critique' style to undermine the target drug (pitolisant) by associating it with failed industry-wide efforts.preempt_rebuttal
83
The slide uses a Q&A format to present expert testimony as evidence of product failure.expose_contradiction
84
The slide uses a Q&A transcript format to build a case against the efficacy of pitolisant based on historical failures at Abbott.preempt_rebuttal
85
The slide uses a Q&A format to build a case against the drug's efficacy based on metabolic pathways.expose_contradiction
86
The slide uses a Q&A format to frame the failure as a known, expected outcome rather than a surprise, highlighting the difficulty of the H3 class.expose_contradiction
87
The slide uses a Q&A transcript format to validate the thesis that the drug class is fundamentally flawed.expose_contradiction
88
Uses expert quotes to establish a 'villain' (the drug class/mechanism) and preemptively rebut its efficacy.name_villain
89
The slide uses expert testimony to undermine the credibility of the company (Bioprojet) and the drug (pitolisant).expose_contradiction
90
The slide uses a Q&A transcript format to validate a negative thesis about the viability of H3 receptor programs.expose_gap
91
The slide uses a Q&A transcript format to validate the thesis that the H3 receptor class is fundamentally flawed.cite_precedent
92
The slide uses a Q&A transcript format to highlight a specific failure case study.expose_contradiction
93
The slide uses a Q&A format to build a case against the safety of a drug program.expose_contradiction
94
The slide uses a Q&A transcript format to corroborate previous claims about drug instability and poor blood-brain barrier penetration.expose_contradiction
95
The slide uses expert testimony to establish a precedent of failure in the H3 receptor space, specifically contrasting J&J's robust trials with Bioprojet's pitocite_precedent
96
The slide uses a Q&A format to discredit the competitor's R&D rigor.expose_contradiction
97
The slide uses highlighted text to emphasize key claims about compound quality and pharmacokinetic challenges.expose_contradiction
98
The slide uses direct quotes from a J&J scientist to undermine the credibility of Bioprojet's research capabilities.name_villain
99
The slide uses a combination of summary bullet points and direct quotes from a consultation call to discredit the competitor's scientific rigor.name_villain
100
The slide uses highlighted text to emphasize key quotes from expert interviews.expose_contradiction
101
The slide uses Q&A format to highlight potential industry knowledge of safety risks that were not publicly disclosed.expose_contradiction
102
Uses Q&A format to frame expert opinion as a critique of Bioprojet's claims.expose_contradiction
103
The slide presents two distinct expert critiques regarding IP expiration and clinical trial quality, attributed to a senior scientist at Johnson & Johnson.name_villain
105
The slide uses a 'quote-and-critique' structure to expose potential data manipulation in clinical reporting.expose_contradiction
106
The slide uses a red box to highlight the 'n=17' discrepancy in the source text.expose_contradiction
107
The slide uses an FDA review document to highlight a safety risk (QTc prolongation) that the company allegedly downplays.expose_contradiction
108
The slide uses a direct quote from a study to argue that 'malaise sensation' is a euphemism for 'fainting' (syncope) to downplay cardiotoxicity.expose_contradiction
109
The slide uses a table to contrast initial high-dose trials with subsequent lower-dose trials to imply company knowledge of toxicity.expose_contradiction
110
The slide uses a 'before-after' or 'comparison' structure to highlight the exclusion criteria in two different trial papers.expose_contradiction
111
The slide uses a 'villain critique' style to highlight a lack of transparency in clinical trial reporting.expose_contradiction
112
The slide uses a 'fraud-exposure' narrative to highlight missing safety data in regulatory filings.preempt_rebuttal
113
The slide uses a critical tone to challenge the integrity of the reported clinical trial data.expose_contradiction
114
The slide uses a critical tone to highlight potential data manipulation or poor reporting practices in a clinical trial publication.expose_contradiction
115
The slide uses a red underline to emphasize the specific clinical findings in the excerpt.expose_contradiction
116
The slide critiques the authors' interpretation of ECG/QTc data in the HAROSA 2 trial, pointing out potential bias or omission.expose_contradiction
118
The slide uses a 'black box' argument to challenge the validity of the sponsor's pharmacokinetic model.expose_contradiction
119
The slide uses direct quotes from the EMA's CHMP assessment report to highlight regulatory discrepancies.expose_contradiction
120
The slide uses a combination of narrative argument and a direct quote from a consultant to build a case against the company's transparency.expose_contradiction
121
The slide presents a direct quote from a PK expert to undermine the validity of the company's safety assertions.expose_contradiction
122
The slide uses a 'before-after' or 'comparison' logic to expose data manipulation in clinical reporting.expose_contradiction
123
The slide uses a red box to highlight a specific data point (40mg dose) in a table to support the argument of inconsistent reporting.expose_contradiction
124
The slide uses a specific FDA review document (NDA 211150) to challenge official plasma level claims.preempt_rebuttal
125
The slide uses a specific data table to support a broader narrative of corporate non-transparency regarding PK data.expose_contradiction
126
The slide uses a table to expose data inconsistencies and safety risks, framing the variability as a 'red flag' regarding the drug's safety profile.expose_gap
127
The slide uses a '>' prefix, suggesting it is a direct, provocative assertion or a 'villain' critique.expose_contradiction
128
The slide uses a direct quote from an FDA clinical review to contradict the company's safety claims, supported by a table of clinical data.expose_contradiction
129
The slide highlights the safety margin between the recommended dose (40mg) and the doses where QTc prolongation was observed (120-240mg), while noting specific preempt_rebuttal
130
The slide uses direct citations from FDA and research documents to highlight the discrepancy between single-dose study designs and the need for steady-state peaexpose_contradiction
131
The slide uses a quote from a pharmacology consultant to argue that safety margins are overestimated due to drug accumulation.expose_contradiction
132
The slide highlights a specific discrepancy in an FDA review document (page 32) where the graph title claims 'steady state Cmax' but the underlying data is fromexpose_contradiction
133
The slide uses a red box to highlight the specific column in the table containing the erroneous data.expose_contradiction
134
The slide documents the source data used by a consultant to derive a linear regression model for QTc vs. plasma levels.analyze_data
135
The slide uses a 'before-after' logic to expose a flaw in regulatory reliance on single-dose data. The red box highlights the critical 'Upper limit TQT' values preempt_rebuttal
136
Includes a linear regression equation Y=14.62*X+53.34 and a scatter plot with error bars.expose_contradiction
138
The slide uses direct excerpts from the drug's prescribing information to build a case against its safety profile.name_villain
139
The slide uses a direct excerpt from a package insert to support the argument that dose reduction is required due to drug interactions.preempt_rebuttal
140
The slide uses a quote from a consultant to challenge the validity of the company's (Harmony) data submitted to the FDA.expose_contradiction
141
The slide uses direct citations from peer-reviewed papers to validate the consultant's findings.preempt_rebuttal
142
The slide uses direct excerpts from regulatory documents to challenge the company's claims regarding drug safety and pharmacokinetics.preempt_rebuttal
143
The slide uses a ClinicalTrials.gov entry as evidence of a 'buried' or incomplete study.expose_contradiction
144
The slide uses a Wikipedia table to demonstrate the complexity of CYP2D6 phenotypes to undermine the validity of the FDA's small-sample study.expose_contradiction
145
The slide contrasts the author's critique with a direct excerpt from an FDA Clinical Pharmacology Review.expose_contradiction
146
The slide uses a 'red flag' narrative to challenge the integrity of clinical trial data reporting.expose_contradiction
147
The slide uses direct excerpts from FDA documents and product labels to highlight a contradiction in clinical trial methodology.expose_contradiction
148
The slide uses a combination of narrative argument and a supporting data table to challenge the safety profile of the drug.preempt_rebuttal
149
The slide uses regulatory documents (EMA/FDA) and primary research (prescriber interviews) to build a case for potential safety risks.preempt_rebuttal
150
The slide uses a specific calculation (153 ng/mL * 4 * 2 = 1224 ng/mL) to quantify risk.preempt_rebuttal
151
Uses anecdotal evidence from Facebook patient support groups to highlight a safety gap.expose_contradiction
152
The slide uses red underlining to highlight specific dangerous medical advice given to patients.expose_contradiction
154
The slide uses a 'villain critique' style to frame the FDA's approval as flawed and the drug's safety as compromised.expose_contradiction
155
The slide uses a narrative summary followed by a supporting table (Table 4) to challenge the safety reporting of the drug.expose_contradiction
156
The slide uses a combination of narrative analysis and a specific case study excerpt to challenge the safety profile of pitolisant.expose_contradiction
157
The slide presents clinical case summaries to address potential safety concerns regarding cardiac events.expose_contradiction
158
The slide uses direct quotes from FDA clinical reviews to highlight the discrepancy between pre-approval assumptions and post-approval safety signals.expose_contradiction
160
The slide highlights the FDA's 'wait-and-see' posture and specific concerns about seizures as a safety signal for the drug pitolisant.preempt_rebuttal
161
The slide uses a 'fraud-exposure' or 'investigative' tone to question the lack of public data on a specific study.expose_contradiction
163
The slide uses a 'villain' narrative to frame the company's non-disclosure as intentional concealment.expose_contradiction
164
The slide uses a combination of original analysis and cited medical literature to challenge the transparency of clinical trial reporting.expose_contradiction
165
The slide uses a 'preempt_rebuttal' strategy by highlighting a specific safety concern (eosinophilic abnormality) that the authors claim was ignored in officialpreempt_rebuttal
166
The slide uses a scientific table to challenge the 'no appreciable binding' claim found in a drug's package insert, citing reproducibility concerns regarding thpreempt_rebuttal
167
The slide uses a medical reference to re-frame clinical trial data that was previously dismissed as unrelated.expose_contradiction
168
The slide uses specific case descriptions to argue for a pattern of respiratory/pulmonary-related deaths.analyze_data
169
The slide uses a direct quote from an FDA clinical review to demonstrate a lack of oversight regarding a specific medical signal.expose_contradiction
170
The slide uses a combination of narrative argument and a cited abstract to highlight a potential safety oversight.expose_contradiction
171
The slide uses two distinct text columns to present evidence from 2008 and 2009 papers regarding the toxicity profile of H3R compounds.preempt_rebuttal
172
The slide uses a specific medical case study to establish a pattern of misdiagnosis and severity, linking it to the current subject (pitolisant).preempt_rebuttal
174
The slide argues that reporting lags or manipulation by Harmony Biosciences obscures the true number of adverse events.expose_contradiction
175
The slide uses a list of adverse events to build a case for cardiotoxicity, highlighting specific fatal and serious outcomes.expose_contradiction
176
The slide highlights specific medical conditions and counts of adverse event reports from the FDA FAERS database.analyze_data
177
The slide highlights a potential contradiction between marketing claims of 'no dependency' and reported withdrawal symptoms.analyze_data
178
The slide highlights a potential discrepancy between official FDA reporting and actual event timing, suggesting either database lag or manufacturer reporting deexpose_contradiction
179
The slide uses a 'back-of-the-envelope' calculation to argue that reported adverse events are undercounted.quantify_opportunity
181
The slide presents a clinical case narrative alongside screenshots of FDA FAERS database records.illustrate_case
182
This is a clinical case report document, likely from an FDA FAERS FOIA request.illustrate_case
183
The slide presents a clinical case study narrative, likely for pharmacovigilance or safety analysis.illustrate_case
184
The slide highlights a potential cover-up or reporting discrepancy regarding a patient seizure.expose_contradiction
185
The slide presents a narrative summary of a medical case report, pointing out suspicious physician/company behavior regarding the reporting of heart palpitationexpose_contradiction
186
The slide presents a clinical case study from the FDA FAERS database, highlighting a potential drug-drug interaction or confounding factor.illustrate_case
187
This is a clinical case report document from the FDA Adverse Event Reporting System (FAERS).illustrate_case
189
The slide presents a clinical case study analysis of a specific adverse event report (FAERS).diagnose_problem
190
This slide presents raw clinical case data from the FDA FAERS database to support a hypothesis about drug interactions.diagnose_problem
191
The slide highlights a discrepancy between patient belief and sponsor assessment regarding drug causality.illustrate_case
192
The slide highlights a specific safety concern regarding pitolisant (Wakix) and its interaction with CYP2D6 inhibitors.expose_contradiction
193
The slide uses a narrative structure to expose a potential cover-up or reporting failure regarding a serious adverse event.expose_contradiction
194
This is a medical case report summary, likely used for pharmacovigilance or safety analysis.illustrate_case
196
The slide presents a specific pharmacovigilance case report, highlighting a positive dechallenge.illustrate_case
197
This is a clinical case study/adverse event report sourced from FDA FAERS data.illustrate_case
198
This appears to be a medical case report document from the FDA FAERS database.illustrate_case
199
This is a clinical case study/adverse event report sourced from FDA FAERS data.illustrate_case
201
The slide presents a patient-reported adverse event (FAERS) to challenge the safety profile of a pharmaceutical product.expose_contradiction
202
The slide explicitly frames the narrative as a potential cover-up, contrasting patient statements with official physician office clarifications.expose_contradiction
204
The slide highlights a discrepancy between the drug's safety profile as presented and the real-world experience of a physician.expose_contradiction
205
The slide presents a qualitative case study (anecdotal evidence) regarding a potential adverse drug event.illustrate_case
206
The slide highlights specific clinical symptoms and diagnostic procedures (EKG, cardiac enzymes, telemetry) used to rule out cardiac issues.illustrate_case
207
The slide uses a Q&A format to document a specific interaction between a doctor and a pharmaceutical sales representative.expose_contradiction
209
The slide uses a table to contrast the clinical trial design with the author's thesis that the evidence standard is too low.expose_contradiction
210
The slide uses a table of clinical trials alongside red-text annotations to highlight the geographic and temporal distance of the studies.expose_contradiction
211
The slide uses a table from a Lancet paper to argue that pitolisant's performance was inferior to modafinil, contradicting the company's narrative.expose_contradiction
212
The slide uses a pie chart to highlight that 38% of study participants were in Russia, suggesting a lack of geographic diversity and potential data manipulationexpose_contradiction
213
The slide uses a combination of narrative text and specific evidence (EMA table and ClinicalTrials.gov record) to prove the existence of a suppressed trial.expose_contradiction
214
The slide uses excerpts from French regulatory documents to prove the existence and negative results of the unpublished HARMONY 4 trial.expose_contradiction
215
The slide functions as a 'fraud-exposure' or 'villain-critique' framework, systematically dismantling the credibility of the clinical trial data.expose_contradiction
216
This slide serves as a critical audit of clinical trial integrity, focusing on statistical manipulation and poor trial design.preempt_rebuttal
217
The slide uses a screenshot of the ESS website to undermine the credibility of the clinical trial endpoint.expose_contradiction
218
The slide uses visual evidence of four different versions of the ESS form to support the claim that the scale lacks a single, consistent format.name_villain
219
The slide uses a 'villain' framing for the Epworth Sleepiness Scale to justify why it should not be used in the context of the research.preempt_rebuttal
220
The slide uses a critical tone to re-evaluate clinical trial data, highlighting the gap between statistical results and clinical meaningfulness.expose_contradiction
221
The slide uses clinical trial data to undermine the efficacy claims of a drug by highlighting the placebo response.expose_contradiction
222
The slide uses FDA biometrics review data to challenge the efficacy timeline of the drug Wakix (pitolisant).expose_contradiction
223
The author argues that the discrepancy hides a trend reversal that would undermine the trial's efficacy claims.expose_contradiction
224
The slide uses a 'red flag' argument to suggest data manipulation or p-hacking via sample size adjustment.expose_contradiction
225
The slide uses a strong, accusatory tone to undermine the validity of the clinical trial results.expose_contradiction
226
The slide uses a direct quote from a Lancet letter to undermine the credibility of the HARMONY 1 trial investigators.expose_contradiction
227
The slide highlights a discrepancy between the reported trial results and the underlying patient-level data regarding dosage and efficacy.expose_contradiction
228
The slide highlights a recurring methodological inconsistency across multiple clinical trials, suggesting regulatory oversight failure.expose_contradiction
229
The slide highlights a specific regulatory failure/contradiction regarding the acceptance of post-hoc analysis in clinical trials.expose_contradiction
230
The slide uses a redacted document image to illustrate the lack of transparency in the FDA's review process compared to the EMA's.expose_contradiction
231
The slide uses a 'villain' framing for the FDA reviewer's oversight.expose_contradiction
232
The slide highlights a discrepancy between raw ESS scores and adjusted LS means, accusing the sponsor of data manipulation.expose_contradiction
233
The slide uses a combination of a pie chart and two tables to substantiate claims of trial design flaws.expose_contradiction
234
The slide details three specific statistical and methodological reasons for the FDA's rejection of the HARMONY 1 study.preempt_rebuttal
235
The slide uses a strong, accusatory tone ('sycophancy', 'red flags') to frame the FDA's regulatory process as flawed.expose_contradiction
236
The slide uses a pie chart to visualize the geographic concentration of trial participants, specifically pointing out the high percentage in Russia to support aexpose_contradiction
237
The slide uses a 'villain' framing to discredit the reliability of clinical data originating from Russia and Eastern Europe.name_villain
238
The slide highlights a discrepancy between the trial paper's log-scale chart and the actual linear-scale data, suggesting data manipulation or misleading presenexpose_contradiction
239
The slide highlights the ambiguity in the definition of 'cataplexy' used in the study protocol, leading to potential data reliability issues.expose_contradiction
240
The slide uses ClinicalTrials.gov record history to demonstrate a 'red flag' in trial reporting.expose_contradiction
241
The slide uses red text for emphasis on specific criticisms (dose response, centre effect).expose_contradiction
242
The slide uses a CONSORT-style flow diagram to illustrate patient attrition in a clinical trial.expose_contradiction
243
The slide uses red boxes and text annotations to highlight specific data points (M6 for ESS, M12 for cataplexy) that contradict expected outcomes.expose_contradiction
244
The slide uses a comparative analysis of clinical trial data to challenge the validity of the HARMONY 3 results.expose_contradiction
245
The slide uses red text and boxes to emphasize the contradiction between the trial paper's claims and the EMA's findings.expose_contradiction
246
This slide appears to be a transition or setup slide for a quote or testimonial that is currently missing or intentionally blank.illustrate_case
247
The slide serves as a qualitative research summary based on 16 expert interviews.summarize
248
This slide presents a series of critical findings regarding market performance, competitive positioning, safety concerns, and marketing practices for the drug Wsummarize
249
The slide presents qualitative interview summaries as evidence of poor market reception.summarize
250
The slide presents anecdotal evidence from four specific prescribers, highlighting skepticism, reimbursement hurdles, and varying levels of adoption.summarize
251
The slide presents qualitative interview summaries highlighting drug discontinuation, safety concerns, and competitive disadvantages.summarize
252
The slide presents qualitative interview data from four distinct medical professionals, highlighting skepticism, lack of efficacy, and safety concerns.summarize
253
The slide presents a qualitative anecdote from a physician interview regarding drug safety.summarize
254
The slide uses direct quotes from a KOL to undermine the market potential of Wakix.expose_contradiction
255
The slide uses a Q&A format to present qualitative feedback from a medical expert.diagnose_problem
256
The slide uses direct quotes from a physician to highlight low adoption and skepticism.expose_contradiction
257
Includes highlighted text emphasizing the shift in sentiment from bullish to skeptical.expose_gap
258
The slide uses a Q&A format to highlight negative sentiment from a key opinion leader (KOL).introduce_nominees
259
The slide highlights a negative expert opinion on drug efficacy, contrasting it with the prescriber's own behavior.expose_contradiction
260
The slide uses a Q&A format to validate the negative sentiment expressed in the summary header.introduce_nominees
261
The slide presents qualitative feedback from a medical professional, highlighting skepticism and administrative barriers.diagnose_problem
262
The slide uses a Q&A format to validate the negative thesis regarding Wakix market performance.expose_contradiction
263
The slide uses a Q&A format to highlight the tightening reimbursement environment for a specific drug.illustrate_case
264
Includes direct quotes from the physician regarding his clinical experience and frustrations with insurance paperwork.introduce_nominees
265
The slide uses a Q&A format to expose the physician's aggressive prescribing behavior and lack of clinical rigor.expose_contradiction
266
The slide highlights the physician's self-proclaimed influence and his personal relationship with sales reps, potentially exposing aggressive marketing tactics.expose_contradiction
267
The slide uses highlighted text to emphasize aggressive prescribing behavior and high patient penetration rates.illustrate_case
268
The slide uses highlighted text to emphasize the doctor's skepticism regarding the drug's 'game-changer' status and the saturation of his patient base.expose_contradiction
269
The slide uses highlighted text to emphasize the doctor's lack of due diligence and surprise at the drug's high cost.expose_contradiction
270
Includes verbatim Q&A excerpts highlighting patient volume and discontinuation rates.introduce_nominees
271
The slide uses highlighted text to emphasize negative feedback from a key opinion leader.expose_contradiction
272
The slide uses a Q&A format to expose negative feedback regarding drug interactions and side effects.introduce_nominees
273
The slide uses a Q&A transcript format to validate the summary points provided at the top.illustrate_case
274
The slide presents qualitative expert testimony regarding drug discontinuation rates.introduce_nominees
275
The slide uses direct quotes from a consultation call to challenge the drug's safety and efficacy profile.expose_contradiction
276
The slide contrasts the prescriber's relaxed attitude toward cardiac/hepatic monitoring with a specific, concerning anecdote about a patient experiencing uncontexpose_contradiction
277
The slide uses a Q&A format to validate the prescriber's credentials and patient volume.introduce_nominees
278
The slide uses a Q&A format to present qualitative feedback from a specific physician.introduce_nominees
279
The slide highlights key negative sentiment regarding market saturation and physician adoption hurdles.summarize
280
The slide highlights potential regulatory/compliance risks (lack of monitoring) and commercial opacity (pricing) regarding the drug Wakix.expose_contradiction
281
The slide presents a transcript of an interview with a physician, highlighting negative clinical experience.illustrate_case
282
The slide uses bolding and highlighting to emphasize negative sentiment from a key opinion leader.expose_contradiction
283
The slide uses a Q&A format to highlight a specific adverse event and the resulting loss of confidence in the drug's safety profile.expose_contradiction
284
The slide uses a Q&A format to document a specific adverse event case study.introduce_nominees
285
The slide uses a Q&A transcript format to detail a specific medical case study involving drug safety concerns.illustrate_case
286
The slide highlights a potential safety concern and a perceived lack of transparency or concern from the manufacturer's sales representative.expose_contradiction
287
The slide uses a Q&A format to provide evidence for the summary points listed in the title.introduce_nominees
289
The slide uses a Wikipedia table to explain DEA drug schedules to frame the competitive landscape.name_villain
290
The slide uses direct quotes from KOLs and specialists to undermine a specific company value proposition.preempt_rebuttal
291
The slide uses a Q&A format to provide expert validation that scheduling is not a significant barrier to prescription.preempt_rebuttal
292
The slide uses direct quotes to expose a contradiction between the company's marketing (non-controlled status) and the actual physician experience (high adminisexpose_contradiction
293
The slide uses highlighted text to emphasize key negative sentiments from expert interviews.expose_contradiction
294
The slide uses a '>' symbol as a bullet point, suggesting a direct critique or callout.expose_contradiction
295
The slide uses a screenshot of the Wakix website to highlight the specific claim being challenged.expose_contradiction
296
The slide uses screenshots of two different websites to demonstrate consistent messaging across patient and HCP channels.expose_contradiction
297
The slide uses a 'preempt_rebuttal' or 'expose_contradiction' style to challenge the scientific validity of a drug's mechanism of action claims.expose_contradiction
298
The slide uses a 'fraud-exposure' approach by highlighting circular citations and methodological weaknesses in the foundational research.expose_contradiction
299
The slide uses scientific data to challenge the validity of the drug's efficacy claims by highlighting the high dosage required in animal models.expose_contradiction
301
The slide uses a specific academic paper to undermine the scientific premise of a drug's mechanism of action.expose_contradiction
302
The slide uses box-whisker plots to demonstrate a lack of correlation between histamine/metabolite levels and various sleep disorder etiologies.expose_contradiction
303
The slide uses a direct excerpt from a scientific paper to undermine a previous scientific claim.expose_contradiction
304
The slide uses a direct quote from a scientific editorial to discredit a previously held hypothesis regarding pitolisant's mechanism of action.expose_contradiction
305
The slide uses underlined text to emphasize key findings that contradict the company's narrative.expose_contradiction
307
The slide uses a combination of narrative argument and direct excerpts from regulatory documents to highlight a discrepancy in drug efficacy claims.expose_contradiction
308
The slide uses a strong accusatory tone, alleging fraudulent claims and intent to mislead the FDA.expose_contradiction
309
The slide uses a combination of summary points and direct excerpts from a pharmacology consultant's review to build a case of scientific negligence or misrepresexpose_contradiction
310
The slide uses a specific scientific paper (Lin et al., 2007) to argue that the drug's mechanism is scientifically implausible based on the provided data.expose_contradiction
311
The slide uses expert testimony and raw data tables to challenge the validity of the reported pharmacokinetics.expose_contradiction
312
The slide uses a combination of summary text, a screenshot of the original study abstract, and a pull-quote from an expert review to discredit the study's findiexpose_contradiction
313
Includes a quote from a pharmacology consultant comparing pitolisant to antihistamines.expose_contradiction
314
The slide uses red boxes and text annotations to highlight specific data points in the charts that contradict expected clinical outcomes.expose_contradiction
316
The slide uses a 'villain' narrative by comparing Harmony's practices to the Insys case and official government fraud alerts.expose_contradiction
317
The slide uses highlighted text to emphasize key admissions of quid pro quo arrangements.expose_contradiction
318
The slide uses direct quotes to expose potential unethical sales practices and reliance on key opinion leaders (KOLs) in the pharmaceutical industry.expose_contradiction
319
The slide uses a Q&A format to validate the thesis of extreme concentration in prescribing behavior.expose_contradiction
320
The slide uses highlighted text to emphasize key admissions regarding prescription volume and the criminal nature of the speaker program.expose_contradiction
321
The slide uses a Q&A format to highlight the 'quid pro quo' nature of the speaker programs.expose_contradiction
322
The slide presents a Q&A transcript excerpt highlighting a potential compliance issue regarding speaker programs and prescription volume.expose_contradiction
323
The slide uses highlighted text to emphasize key admissions of fraud/inducement.expose_contradiction
324
The slide uses a '>' character as a bullet point/indicator for the thesis statement.expose_contradiction
325
The slide uses a 'fraud-exposure' narrative by contrasting the official label with market reality.expose_contradiction
326
The slide uses direct quotes from former territory managers to substantiate allegations of fraudulent marketing practices.expose_contradiction
327
The slide uses a Q&A transcript format to expose potentially fraudulent sales practices.expose_contradiction
328
The slide uses highlighted text to emphasize key allegations regarding pressure and compensation.expose_contradiction
329
The slide uses a Q&A format to document unethical sales practices, specifically the verbal instruction to expand diagnoses to meet off-label sales goals.expose_contradiction
330
Includes a Q&A transcript excerpt highlighting the 'buddy' system used to submit fake referrals.expose_contradiction
331
The slide uses a Q&A format to highlight discrepancies in prescription volumes across similar-sized territories.expose_contradiction
332
The slide uses a Q&A format to present whistleblower testimony regarding unethical sales practices.expose_contradiction
333
The slide uses direct quotes to expose potential unethical or illegal marketing practices.expose_contradiction
334
The slide uses direct quotes from former territory managers to establish the 'unusual' nature of the compensation plan.expose_contradiction
335
The slide uses direct quotes from two different ex-Harmony territory managers to build a case of systemic non-compliance and arbitrary quota setting.expose_contradiction
336
The slide uses a Q&A transcript format to highlight the 'weird' nature of the compensation process at Harmony.expose_contradiction
337
The slide uses a Q&A transcript format to highlight alleged unethical practices and lack of transparency in sales compensation.expose_contradiction
338
Includes direct Q&A transcript excerpts highlighting the alleged lack of transparency and short-term focus.expose_contradiction
339
The slide uses direct quotes to highlight operational inefficiencies and potential lack of transparency in the patient services process.expose_contradiction
340
The slide uses a Q&A format to highlight the discrepancy between industry standards and Harmony's practices.expose_contradiction
341
The slide uses highlighted text to emphasize key phrases from expert interviews.expose_contradiction
342
The slide uses a Q&A format to build a case for regulatory or ethical misconduct.expose_contradiction
343
The slide uses a combination of narrative summary and Q&A transcript to build a case of corporate malfeasance.expose_contradiction
344
The slide uses a Q&A format to expose a scheme where management facilitates off-label marketing.expose_contradiction
345
The slide uses a Q&A format to document testimony regarding corporate fraud and off-label promotion.expose_contradiction
346
The slide uses a Q&A transcript format to substantiate claims of unethical sales practices.expose_contradiction
347
The slide uses a Q&A transcript format to highlight the interviewee's cynical view on the prevalence of the disease.expose_contradiction
348
The slide uses a Q&A format to expose a potential business practice of incentivizing off-label drug prescriptions.expose_contradiction
349
The slide uses a Q&A transcript format to build a case of fraudulent business practices.expose_contradiction
350
The slide uses highlighted text to emphasize key admissions of fraudulent behavior.expose_contradiction
351
The slide uses a Q&A transcript format to highlight potential violations of the Stark Law.expose_contradiction
352
The slide uses highlighted text to emphasize key allegations of regulatory non-compliance and unethical sales practices.expose_contradiction
353
The slide uses a Q&A format to highlight systemic issues and potential regulatory non-compliance regarding speaker programs and off-label prescriptions.expose_contradiction
354
The slide uses highlighted text to emphasize key allegations of off-label promotion and retaliation against employees.expose_contradiction
355
The slide uses a Q&A format to build a narrative of corporate malfeasance.expose_contradiction
356
The slide uses Q&A format to present expert testimony regarding potential regulatory violations and mismanagement.expose_contradiction
358
The slide uses direct quotes from former employees to validate the thesis of market saturation and internal company struggles.expose_contradiction
359
The slide uses a Q&A format to validate the thesis that high-volume prescribers quickly exhaust their patient pool and face insurance hurdles, contradicting potexpose_contradiction
360
Includes verbatim interview transcripts highlighting the 'crash' after initial launch spikes.expose_contradiction
361
The slide uses highlighted text to emphasize key claims about PIPs and quota misalignment.expose_contradiction
362
The slide uses direct quotes from ex-managers to highlight a shift in company culture towards aggressive performance management.expose_contradiction
363
The slide uses a Q&A format to validate the thesis of a slowing business.expose_contradiction
364
The slide uses direct quotes from a KOL to contradict the company's narrative of market growth.expose_contradiction
365
The slide uses direct Q&A transcripts to validate the thesis that the product has hit a growth ceiling.expose_gap
366
The slide uses direct quotes from physician interviews to build a negative case against the product's market performance.name_villain